Making Africa a competitor in the Global Pharmaceutical Industry: Implementation of the Pharmaceutical
Manufacturing Plan for Africa AWA Consultative Experts’ Committee Meeting of
Commission of the African Union, Nouakchott, Mauritania
27-28 May 2014
Dr Paul Lartey, FAPMA Chairperson
Africa’s Public Health Challenges
• Heavy burden of HIV/AIDS: top cause of morbidity and mortality in Sub-Sahara Africa;
• Upsurge in tuberculosis and other opportunistic infections;• Future disease burden
– 60 million people with hypertension by 2020– 1 million cases of cancer annually– 18.6 million people with diabetes by 2020– Other CVS, chronic respiratory diseases (COPD / asthma) and
neuro-psychiatric conditions – NCD’s will have surpassed infectious diseases as the leading
cause of death in Africa by 2030.Source: WHO, WHO AFRO, Frost & Sullivan analysis
Pharmaceutical Manufacturing Plan for Africa - PMPA
• African Heads of State recognized the need for a sustainable strategy with treatment as central point
• This in turn implies the need for readily available efficacious, high quality and affordable medicines
• AU Heads of State meeting of July 2012 accepted the PMPA Business Plan
PMPA Vision
To develop a competitive and enduring integrated pharmaceutical manufacturing industry in Africa, able to respond to the
continent’s need for a secure and reliable supply of quality, affordable, accessible,
safe and efficacious medicines.
4
Key Issues and Package of Solutions
6
Active in Entire Pharma Value Chain
Research into Neglected Diseases
Date/Place Agreement Objective/Declaration
June, 2007Noordwijk-aan-Zee, Netherlands
The Noordwijk medicines Agenda adopted by the Organization for Economic Cooperation and Development.
Encourage a model for the innovation and development of medicines for neglected and emerging infectious diseases affecting developing countries.
May, 2008Geneva, Switzerland
61st World Health Assembly adopted the Global strategy and plan of action on public health, innovation and intellectual property.
All UN member states should promote technological innovation and the transfer of technology to developing countries, as supported by intellectual property rights.Strengthen the innovative capacity of developing countries as an essential response to the needs of public health.
March, 2009Yaoundé, Cameroon
Strengthening health innovations: from agendas to action
Encourages a broader African perspective on health innovations.
PMPA: Partnering for Implementation
• World health Organization (WHO) and United States Pharmacopeia convention’s Promoting the Quality of Medicines program. – These organizations are assisting with capacity development in
regulation and GMP. • The United Nations Industrial Development Organization (UNIDO) is
playing a much-needed coordinating role in the implementation of the PMPA BP, through a consortium comprising representation from all stakeholders.
• Other partners are the United Nations Development Program (UNDP), the Joint United nations Program on HIV/AIDS (UNAIDS), United Nations Population Fund (UNFPA) and the African Development Bank.
Federation of African Pharmaceutical Manufacturers Associations
9
Member Organizations:
•Federation of East African Pharmaceutical Manufacturers
•Southern African Generic Medicines Association
•West African Pharmaceutical Manufacturers Association
FAPMA Membership
10
FAPMA231 manufacturers
11
FAPMA Objectives
To promote excellence in the pharmaceutical industry
Promote access to safe, quality, efficacious medicines in Africa
To strengthen local production of medicines so as to meet needs of the continent
Facilitate economic growth through development of a sustainable, self-sufficient and viable pharmaceutical industry in Africa industry
Factors impacting on industry capacity
• Unfair competition from fake and substandard imported medicines
• Price competition against imported highly subsidized medicines from Asia
• Inadequate patronage by African governments
Way Forward
• Aligned visions of PMPA BP and FAPMA demonstrates commitment
• Mix of capacity development measures, incentives and patronage, strengthen of 236 Africa-based pharmaceutical manufacturers
Global competitiveness is imminently possible